Leukoencephalopathy induced by low-dose methotrexate in a patient with rheumatoid arthritis

Internal Medicine

Volumn 50, Issue 19, 2011, Pages 2219-2222

  Matsuda, Masayuki ^a   Kishida, Dai ^a   Kinoshita, Tomomi ^a   Hineno, Akiyo ^a   Shimojima, Yasuhiro ^a   Fukushima, Kazuhiro ^a   Ikeda, Shu Ichi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Leukoencephalopathy; Methotrexate; Rheumatoid arthritis

Indexed keywords

DEXAMETHASONE; METHOTREXATE; PREDNISOLONE; STROMELYSIN;

AGED; AMNESIA; ARTHRALGIA; ARTICLE; BONE EROSION; CASE REPORT; DIZZINESS; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; FEMALE; HEMIANOPIA; HUMAN; JOINT LIMITATION; JOINT SWELLING; LEUKOENCEPHALOPATHY; LOW DRUG DOSE; METACARPOPHALANGEAL JOINT; MORNING STIFFNESS; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PHYSICAL EXAMINATION; RHEUMATOID ARTHRITIS;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DEXAMETHASONE; FEMALE; HUMANS; LEUKOENCEPHALOPATHIES; MAGNETIC RESONANCE IMAGING; METHOTREXATE;

EID: 80053515681     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.50.5552     Document Type: Article

References (19)

1. Weinblatt ME. Toxicity of low dose methotrexate in rheumatoid arthritis. J Rheumatol 12 (Suppl 12): 35-39, 1983.
2. Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low dose methotrexate in rheumatoid arthritis. N Engl J Med 312: 818-822, 1985.
3. Kremer JM, Lee JK. The safety and efficacy of the use of methotrexate in long-term therapy in rheumatoid arhthritis. Arthritis Rheum 29: 822-831, 1986.
4. Wernick R, Smith DL. Central nervous system toxicity associated with weekly low dose methotrexate treatment. Arthritis Rheum 32: 770-775, 1989.
5. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31: 315-324, 1988.
6. Henderson RD, Rajah T, Nicol AJ, Read SJ. Posterior leukoencephalopathy following intrathecal chemotherapy with MRAdocumented vasospasm. Neurology 60: 326-328, 2003.
7. Oka M, Terae S, Kobayashi R, et al. MRI in methotrexate-related leukoencephalopathy: disseminated necrotizing leukoencephalopathy in comparison with mild leukoencephalopathy. Neuroradiology 45: 493-497, 2003.
8. Bartynski WS. Posterior reversible encephalopathy syndrome. Part 1: fundamental imaging and clinical features. AJNR Am J Neuroradiol 29: 1036-1042, 2008.
9. Bartynski WS. Posterior reversible encephalopathy syndrome. Part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol 29: 1043-1049, 2008.
10. Bleyer WA, Drake JC, Chabner BA. Neurotoxicity and elevated cerebrospinal fluid methotrexate concentration in meningeal leukaemia. N Engl J Med 289: 770-773, 1973.
11. Weiss HD, Walker MD, Wiernik PH. Neurotoxicity of commonly used antineoplastic agents. N Engl J Med 291: 75-81, 1974.
12. Price RA, Jamieson PA. The central nervous system in childhood leukemia. II. Subacute leukoencephalopathy. Cancer 35: 306-318, 1975.
13. Worthley SG, McNeil JD. Leukoencephalopathy in a patient taking low dose oral methotrexate therapy for rheumatoid arthritis. J Rheumatol 22: 335-337, 1995.
14. Yokoo H, Nakazato Y, Harigaya Y, Sasaki N, Igata Y, Itoh H. Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. Acta Neuropathol 114: 425-430, 2007.
15. Krishnamoorthy T, Radhakrishnan VV, Kuruvilla A. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. Eur J Neurol 14: 309-314, 2007.
16. Renard D, Westhovens R, Vandenbussche E, Vandenberghe R. Reversible posterior leukoencephalopathy during oral treatment with methotrexate. J Neurol 251: 226-228, 2004.
17. Marcon G, Giovagnoli AR, Mangiopane P, Erbetta A, Tagliavini F, Girotti F. Regression of chronic posterior leukoencephalopathy after stop of methotrexate treatment. Neurol Sci 30: 375-378, 2009.
18. Markowsky SJ, Zimmermann CL, Tholl D, Soria I, Castillo R. Methotrexate disposition following disruption of the blood-brain barrier. Ther Drug Monit 13: 24-31, 1991.
19. Filley CM, Kleinschmidt-DeMasters BK. Toxic leukoencephalopathy. N Engl J Med 345: 425-432, 2001.